PHIO is the ticker symbol for Phio Pharmaceuticals Corp., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks PHIO with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is PHIO a good stock to buy?

PHIO is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/PHIO.

Where does 13F Pro source PHIO data?

All Phio Pharmaceuticals Corp. fundamentals and ownership data come directly from SEC EDGAR. Phio Pharmaceuticals Corp. files with the SEC under CIK 1533040. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Phio Pharmaceuticals Corp.(PHIO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Phio Pharmaceuticals Corp. (PHIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PHIO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.4m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Phio Pharmaceuticals Corp. reports net income of $-4.1M, free cash flow of $-4.0M. Top institutional holders of PHIO by reported 13-F value include JANE STREET GROUP, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PHIO trades on the Nasdaq exchange and files with the SEC under CIK 1533040. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Phio Pharmaceuticals Corp. directly from SEC EDGAR.

Net Income

$-4.1M

Free Cash Flow

$-4.0M

PHIO key financials by period

Phio Pharmaceuticals Corp. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2019	10-K	$21.0K	$-8.9M	—
FY 2018	10-K	$138.0K	$-7.4M	—
FY 2017	10-K	$15.0K	$-12.5M	—
FY 2016	10-K	$19.0K	$-9.0M	—
FY 2015	10-K	$34.0K	$-10.2M	—
FY 2013	10-K	$399.0K	$-20.9M	—

Institutions holding PHIO

Institutional investors reporting a position in Phio Pharmaceuticals Corp. on SEC Form 13F.
Institution	Shares	Value	Reported
JANE STREET GROUP	117,755	$120.7K	2026-06-30
GEODE CAPITAL MANAGEMENT	114,574	$117.4K	2026-06-30
VANGUARD CAPITAL MANAGEMENT	94,262	$96.6K	2026-06-30
NOMURA ASSET MANAGEMENT INTERNATIONAL	50,000	$51.0K	2026-06-30
Cetera Investment Advisers	47,500	$48.7K	2026-06-30
CITADEL ADVISORS	47,150	$48.3K	2026-06-30
VANGUARD FIDUCIARY	38,169	$39.1K	2026-06-30
NORTHERN	27,768	$28.5K	2026-06-30
TWO SIGMA INVESTMENTS	21,501	$22.0K	2026-06-30
XTX Topco Ltd	18,475	$18.9K	2026-06-30

SEC EDGAR: CIK 1533040 →

Phio Pharmaceuticals Corp.

PHIO

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.4M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.